Pfizer Inc., PFE, FDA Calendar, PDUFA Date

Company Name	Pfizer Inc. PFE
Drug Name	Vepdegestrant (NDA)
Event Name	FDA decision on Vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced breast cancer
Event Date	06/05/2026
Outcome Date
Outcome	Pending
Drug Status	Vepdegestrant is being co-developed by Arvinas and Pfizer
Rival Drugs	Menarini's Orserdu, AstraZeneca's Faslodex
Market Potential	If approved Vepdegestrant could achieve peak sales of $2 billion to $4 billion, according to analysts
Other Approvals
News

Return to FDA Calendar

Slide Shows